Impact of prior treatment on selinexor, bortezomib, dexamethasone outcomes in patients with relapsed/refractory multiple myeloma: Extended follow-up subgroup analysis of the BOSTON trial.
Maria-Victoria MateosMonika EngelhardtXavier LeleuMercedes Gironella MesaMichele CavoMeletios- Athanasios DimopoulosMartina BiancoGiovanni Marino MerloCharles la PortePaul Gerard RichardsonPhillipe MoreauPublished in: European journal of haematology (2024)
With over 2 years of follow-up, these clinically meaningful outcomes further support the use of SVd in patients who are lenalidomide-refractory, PI-naïve, bortezomib-naïve, or who received 1LOT (including a monoclonal antibody) and underscore the observed synergy between selinexor and bortezomib.
Keyphrases
- multiple myeloma
- monoclonal antibody
- newly diagnosed
- end stage renal disease
- chronic kidney disease
- ejection fraction
- phase iii
- clinical trial
- peritoneal dialysis
- low dose
- high dose
- randomized controlled trial
- prognostic factors
- patient reported outcomes
- acute myeloid leukemia
- combination therapy
- insulin resistance
- skeletal muscle
- replacement therapy
- weight loss
- patient reported